February 20, 2025 Vivli and RDCA-DAP Present: Data Platform Partnerships to promote Rare Disease Data Sharing Join Julie Wood, Chief Operating Officer at Vivli, for an engaging webinar, Thursday, February 20, where she’ll discuss...
February 19, 2025 Advancing Neonatal Drug Development Through Collaboration At C-Path’s INC, we believe that meaningful progress in neonatal drug development...
February 19, 2025 C-Path’s eCOA Consortium Welcomes Veeva System and VPG Health as Newest Partners C-Path's eCOA Consortium is thrilled to welcome Veeva Systems and VPG Health...
February 13, 2025 Breaking the silence: challenges and opportunities in pediatric drug development Pediatric drug development faces significant challenges, including underfunding, ethical concerns, and complex regulatory...
January 31, 2025 Integrating Complex In Vitro Models Into the Regulatory Pipeline C-Path has developed a framework to support FDA qualification of CIVMs for use in regulatory submissions.
January 21, 2025 Save the Date: CGIC Returns to D.C. this September We are thrilled to invite you to the 2025 Critical Path Institute® (C-Path) Global Impact Conference (CGIC)...
January 17, 2025 FDA Accepts Qualification Plan for Urine Biomarker Panel to Allow Earlier Detection of Response to Drug-Induced Kidney Injury in Clinical Trials The Foundation for the National Institutes of Health (FNIH) and Critical Path Institute® (C-Path)...
January 17, 2025 CP-RND ALS Public-Private Partnership Public Forum A public forum for stakeholders Critical Path Institute's (C-Path) Critical Path for Rare and Neurodegenerative Diseases...
January 15, 2025 C-Path Welcomes Bayer Pharma as Newest Member of CPP C-Path is excited to welcome Bayer Pharma as a the newest member of the organization's Critical Path for Parkinson’s (CPP)...
November 27, 2024 C-Path’s Romero, Swingle Named to 100 Most Innovative and Influential Healthcare Leaders in AZ Big Media C-Path CEO Klaus Romero and President & COO Kristen Swingle, President and COO were recently named to the 100 Most...
